US pharma major Merck (NYSE: MRK) has reported a Phase III success for Welireg (belzutifan) plus Keytruda (pembrolizumab) as ...

French biotech OSE Immunotherapeutics (Euronext Paris: OSE) is accelerating a strategic reset, pausing development of OSE-230 and discontinuing certain early research programs to concentrate capital ...

Danish vaccine maker Bavarian Nordic announced today, that the board of directors has entered into an agreement with CEO, Paul Chaplin, who wishes to step down for personal reasons.

United Therapeutics has announced that its long-term pivotal Phase III ADVANCE OUTCOMES study met its primary endpoint, with ralinepag reducing the risk of a clinical worsening event by 55% compared ...